Understanding Potential Ocular Side Effects of Injectable GLP-1 Medications

Key Takeaways

• Semaglutide linked to rare NAION cases in recent studies.
• Choi et al. (2026) found higher NAION incidence among GLP-1RA users.
• Diabetes patients already face elevated eye-stroke risk, complicating causality.
• Ongoing safety reviews may affect prescribing guidelines for weight-loss drugs.

Pulse Analysis

Injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide have reshaped diabetes management and weight-loss therapy, driving multi-billion-dollar sales worldwide. Their ability to lower HbA1c, reduce cardiovascular events, and produce substantial weight loss has earned enthusiastic adoption by clinicians and patients alike. Yet, as prescription volumes surge, post-marketing surveillance is uncovering rare adverse events that were not apparent in pivotal trials. Among the most concerning signals is a potential association between GLP-1RAs and non-arteritic anterior ischemic optic neuropathy (NAION), an acute “eye stroke” that can cause permanent vision loss.

The link first surfaced in case reports linking semaglutide (marketed as Ozempic and Wegovy) to sudden visual field deficits, prompting a lawsuit alleging drug-induced blindness. A 2026 JAMA Network Open analysis by Choi et al. compared incidence rates of NAION among users of GLP-1RAs and SGLT2 inhibitors, finding a modest but statistically significant elevation for the former. While the absolute risk remains low—estimated at fewer than one case per 10,000 patient-years—the signal is amplified by the fact that type 2 diabetes itself predisposes patients to microvascular eye disease. Researchers caution that confounding factors, such as baseline vascular health and concurrent medications, must be untangled before assigning causality.

For clinicians, the emerging evidence translates into a need for heightened vigilance: baseline ophthalmologic assessment, patient education about sudden visual changes, and prompt referral to an eye specialist are now prudent steps when initiating GLP-1RA therapy. Regulators may also revisit labeling requirements, potentially adding warnings similar to those for other drugs with rare ocular toxicity. From a market perspective, any perception of safety concerns could temper the rapid growth of GLP-1RA prescriptions, especially among weight-loss consumers without diabetes. Ongoing pharmacovigilance studies and prospective trials will be essential to quantify risk, identify high-risk subpopulations, and guide evidence-based prescribing.